Cartesian Therapeutics, Inc. (RNAC) Balance Sheet

The persistent gap between total liabilities ($443.9M) and total assets ($318.6M) has produced a structural negative equity position that cannot be explained by operating losses alone, implying significant non-operating obligations sit on the balance sheet. The trajectory suggests the company is consuming its remaining asset base through R&D spending with no offsetting revenue stream, consistent with the income statement's collapse to zero revenue and the cash flow statement's persistent burn.

This abrupt debt increase, arriving alongside deteriorating cash reserves and deeply negative equity, suggests a potential refinancing or new credit facility that warrants closer examination of terms, covenants, and maturity schedules. With equity deeply negative, conventional leverage ratios are uninterpretable, and the company's ability to service this higher debt load appears to depend entirely on continued capital market access rather than operating cash generation — a fragile foundation given zero revenue.

The magnitude of accumulated losses relative to total assets ($318.6M) suggests the business model has destroyed more value than the current balance sheet carries, with the deficit reflecting not just operating losses but potentially large non-cash write-downs visible in the cumulative net income versus operating cash flow divergence. For a clinical-stage biotech with zero revenue, this accumulated deficit raises material dilution risk, as any future equity financing would likely need to be priced at a significant discount to restore positive book value.

The current ratio is artificially inflated by minimal current liabilities relative to remaining cash, but the absolute cash trajectory is the more telling metric given zero revenue and persistent operating losses of ~$20M+ per quarter. At the observed burn rate implied by the cash decline, investors should closely monitor how many quarters of runway remain before the company must access capital markets again — particularly given the negative equity position that may complicate future financing terms.